Characteristics | N (103) |
---|---|
Age, mean ± SD, in years | 51.3 ± 12.6 |
BMI, mean ± SD, in kg/m2 | 23.2 ± 6.1 |
Chemotherapy, N (%) | |
Antimetabolite (5-FU, capecitabine, gemcitabine, methotrexate) | 41 (39.8) |
Anthracycline (doxorubicin, epirubicin) | 40 (38.8) |
Alkylating agents (cyclophosphamide) | 34 (33) |
Taxane (docetaxel, paclitaxel) | 36 (34.9) |
Platinum (carboplatin, cisplatin) | 23 (22.3) |
Vinca alkaloid (vinorelbine) | 2 (1.9) |
Antimicrotubule (eribulin) | 2 (1.9) |
Histopathology, N (%) | |
NST | 95 (92.2) |
Lobular | 3 (2.9) |
Others (metaplastic, papillary, medullary) | 5 (4.9) |
Histo grade, N (%) | |
I | 1 (1) |
II | 33 (32) |
III | 56 (54.4) |
N/A | 13 (12.6) |
Ki-67, N (%) | |
< 20% | 10 (9.7) |
≥ 20% | 89 (86.4) |
N/A | 4 (3.9) |
Site of metastasis, N (%) | |
Bone | 51 (49.5) |
Lung | 58 (56.3) |
Liver | 30 (29.1) |
Brain | 11 (10.7) |
Others (adrenal, soft tissue) | 2 (1.9) |